Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.38, with a high estimate of $12.00 and a low estimate of $0.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 43.69%.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Lyra Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Caufield | HC Wainwright & Co. | Announces | Neutral | $2.00 | - |
| Dennis Ding | Jefferies | Lowers | Hold | $0.50 | $10.00 |
| Matthew Caufield | HC Wainwright & Co. | Maintains | Buy | $12.00 | $12.00 |
| Jason Gerberry | B of A Securities | Lowers | Buy | $11.00 | $12.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lyra Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lyra Therapeutics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lyra Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Lyra Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Lyra Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Lyra Therapeutics
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Understanding the Numbers: Lyra Therapeutics's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Lyra Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 29.76%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Lyra Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -4220.3%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Lyra Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -26.9%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Lyra Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -15.8%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Lyra Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.